公开(公告)号：US20230322900A1

公开(公告)日：2023-10-12

申请号：US18064571

申请日：2022-12-12

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Volker Schellenberger ,  Pei-Yun Chang ,  Fatbardha Varfaj ,  Sheng Ding ,  Joshua Silverman ,  Chia-wei Wang ,  Benjamin Spink ,  Willem P. Stemmer ,  Nathan Geething ,  John Kulman ,  Tongyao Liu ,  Garabet G. Toby ,  Haiyan Jiang ,  Robert Peters ,  Deping Wang ,  Baisong Mei

IPC: C07K14/755

CPC classification number: C07K14/755 ,  A61K38/00

Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.

公开(公告)号：US11193116B2

公开(公告)日：2021-12-07

申请号：US15619196

申请日：2017-06-09

Applicant: Bioverativ Therapeutics Inc.

Inventor： Glenn Pierce ,  Samantha Truex ,  Robert T. Peters ,  Haiyan Jiang ,  Mark Brader

IPC: A61K38/36 ,  C12N9/64 ,  C07K14/745 ,  C07K16/36 ,  A61K38/00

Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.

公开(公告)号：US20200318140A1

公开(公告)日：2020-10-08

申请号：US16839947

申请日：2020-04-03

Applicant: Bioverativ Therapeutics, Inc. ,  MaxCyte, Inc. ,  Sangamo Therapeutics, Inc.

Inventor： Siyuan Tan ,  Dale Ando ,  Andreas Reik ,  Linhong Li ,  Madhusudan V. Peshwa ,  Haiyan Jiang

IPC: C12N15/90 ,  A61K48/00 ,  C12N15/87

Abstract: Disclosed herein are methods and compositions for increasing RNA activity in a cell.

公开(公告)号：US10561714B2

公开(公告)日：2020-02-18

申请号：US15890284

申请日：2018-02-06

Applicant: Bioverativ Therapeutics Inc.

Inventor： Glenn Pierce ,  Samantha Truex ,  Robert T. Peters ,  Haiyan Jiang

IPC: A61K38/36 ,  A61K38/48 ,  A61K47/64 ,  A61K39/395 ,  C12N9/96 ,  A61K38/38 ,  C07K16/18 ,  C12N9/64 ,  C07K14/76 ,  A61K9/00 ,  A61P7/04

Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US11286528B2

公开(公告)日：2022-03-29

申请号：US16246225

申请日：2019-01-11

Applicant: Bioverativ Therapeutics Inc. ,  Puget Sound Blood Center

Inventor： Haiyan Jiang ,  Tongyao Liu ,  Sriram Krishnamoorthy ,  Neil Josephson ,  Glenn Pierce

IPC: C07K14/755 ,  C12Q1/6883 ,  A61K38/21 ,  A61K39/00 ,  A61K38/37 ,  A61K47/68

Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

公开(公告)号：US10568943B2

公开(公告)日：2020-02-25

申请号：US16271686

申请日：2019-02-08

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Glenn Pierce ,  Samantha Truex ,  Robert T. Peters ,  Haiyan Jiang

IPC: A61K38/36 ,  A61K38/48 ,  A61K47/64 ,  A61K39/395 ,  C12N9/96 ,  A61K38/38 ,  C07K16/18 ,  C12N9/64 ,  C07K14/76 ,  A61K9/00 ,  A61P7/04

Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US10221455B2

公开(公告)日：2019-03-05

申请号：US14371931

申请日：2013-01-12

Applicant: Bioverativ Therapeutics Inc. ,  Puget Sound Blood Center

Inventor： Haiyan Jiang ,  Tongyao Liu ,  Sriram Krishnamoorthy ,  Neil Josephson ,  Glenn Pierce

IPC: C07K14/755 ,  C12Q1/6883 ,  A61K38/37 ,  A61K38/21 ,  A61K39/00 ,  A61K47/68

Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

公开(公告)号：US09867873B2

公开(公告)日：2018-01-16

申请号：US14982934

申请日：2015-12-29

Applicant: Bioverativ Therapeutics Inc.

Inventor： Glenn Pierce ,  Samantha Truex ,  Robert T. Peters ,  Haiyan Jiang

IPC: C07K14/755 ,  A61K38/48 ,  A61K39/395 ,  C12N9/96 ,  A61K38/38 ,  C07K16/18 ,  C12N9/64 ,  C07K14/76 ,  A61K9/00 ,  A61K47/48

CPC classification number: A61K38/4846 ,  A61K9/0019 ,  A61K38/38 ,  A61K39/395 ,  A61K39/39533 ,  A61K39/3955 ,  A61K47/643 ,  C07K14/76 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/90 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/33 ,  C12N9/644 ,  C12N9/96 ,  C12Y304/21022

Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US09675676B2

公开(公告)日：2017-06-13

申请号：US15043445

申请日：2016-02-12

Applicant: Bioverativ Therapeutics Inc.

Inventor： Glenn Pierce ,  Samantha Truex ,  Robert T. Peters ,  Haiyan Jiang

IPC: A61K38/38 ,  A61K38/48 ,  A61K39/395 ,  C12N9/96 ,  C07K16/18 ,  C12N9/64 ,  C07K14/76 ,  A61K9/00 ,  A61K47/48

CPC classification number: A61K38/4846 ,  A61K9/0019 ,  A61K38/38 ,  A61K39/395 ,  A61K39/39533 ,  A61K39/3955 ,  A61K47/643 ,  C07K14/76 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/90 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/33 ,  C12N9/644 ,  C12N9/96 ,  C12Y304/21022

Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US11091534B2

公开(公告)日：2021-08-17

申请号：US16154310

申请日：2018-10-08

Applicant: Bioverativ Therapeutics Inc.

Inventor： Ekta Seth Chhabra ,  Tongyao Liu ,  Pei-yun Chang ,  Robert T. Peters ,  John Kulman ,  Haiyan Jiang

IPC: C07K14/755 ,  A61K47/55 ,  A61K38/36 ,  A61K38/37 ,  C07K16/00 ,  C12N15/11

Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.